Yeojeong Jane So,Anne Fraser,Gareth Rivalland et al.
Yeojeong Jane So et al.
Introduction: EGFR tyrosine kinase inhibitors (TKIs) are more effective than chemotherapy in patients with EGFR-mutant NSCLC. Disease progression on EGFR TKI therapy occurs most often owing to acquired resistance from the...
Jiaxi He,Shuben Li,Hui Pan et al.
Jiaxi He et al.
Introduction: Adenosquamous lung cancer (ASC) is a rare type of NSCLC with poor prognosis. There is no consensus on the necessity of adjuvant chemotherapy and the selection of surgical procedures for patients with early s...
Desensitizing Effect of Cancer Cachexia on Immune Checkpoint Inhibitors in Patients With Advanced NSCLC [0.03%]
癌症恶病质对晚期非小细胞肺癌患者免疫检查点抑制剂的脱敏作用
Taichi Miyawaki,Tateaki Naito,Akihro Kodama et al.
Taichi Miyawaki et al.
Introduction: Programmed cell death 1 (PD-1) inhibitors have become standard treatment for patients with advanced NSCLC. However, few studies have focused on the impact of cancer cachexia on the efficacy of PD-1 or progra...
Validation of the Proposed cN2 Subclassification in the Eighth Edition of the IASLC Staging System: A Prospective Phase II Multicenter Study [0.03%]
第八版IASLC分期系统建议的cN2分型验证：一项前瞻性二期多中心研究
Jiro Abe,Yuji Matsumura,Satoshi Shiono et al.
Jiro Abe et al.
Introduction: Surgery for N2 stage IIIA NSCLC is not recommended in major guidelines. Nevertheless, it has been noted that single-station N2 may have a better prognosis than multistation N2 and that surgery can be perform...
Tumor Atelectasis Gives Rise to a Solid Appearance in Pulmonary Adenocarcinomas on High-Resolution Computed Tomography [0.03%]
肺腺癌的肿瘤性肺不张在高分辨率计算机断层扫描中产生实性表现
Francesca Ambrosi,Birgit Lissenberg-Witte,Emile Comans et al.
Francesca Ambrosi et al.
Introduction: Ground-glass opacities in a high-resolution computed tomography (HR-CT) scan correlate, if malignant, with adenocarcinoma in situ. The solid appearance in the HR-CT is often considered indicative of an invas...
Saro Kasparian,Cesar Gentille,Ethan Burns et al.
Saro Kasparian et al.
Introduction: Immune-checkpoint inhibitors (ICIs) are transforming the modern era of cancer therapy. As new treatment options are becoming available, new patterns of disease behavior are manifesting. One such phenomenon, ...
Dramatic Response to Teriprilumab and Anlotinib Combination Therapy in a patient with EGFR-Mutant Lung Adenocarcinoma Who Experienced Small-Cell Transformation-Mediated Erlotinib Resistance After Failure of Chemotherapy [0.03%]
酪立普利单抗和安罗替尼联合治疗对一位化疗失败后小细胞转化介导的厄洛替尼耐药的EGFR突变肺腺癌患者的戏剧性疗效
Yuling Zhou,Liang Zeng,Nong Yang et al.
Yuling Zhou et al.
Clinical Benefit From a Combination of Brigatinib and Camrelizumab in Sarcomatoid Transformation of ALK-Rearranged Squamous Cell Lung Cancer Resistant to Crizotinib [0.03%]
克唑替尼耐药的ALK重排鳞状细胞肺癌肉瘤样变中brigatinib和camrelizumab联合使用的临床益处
Wei Jiang,Ruting Guan,Yang W Shao et al.
Wei Jiang et al.
Young J Lee,Jae S Jeong,So R Kim et al.
Young J Lee et al.
Lorlatinib-Induced Pulmonary Embolism in a Patient With an ALK-Positive NSCLC [0.03%]
劳拉替尼致一位ALK阳性非小细胞肺癌患者的肺栓塞事件
Ryo Toyozawa,Naoki Haratake,Gouji Toyokawa et al.
Ryo Toyozawa et al.